The “war” on cancer: are we “winning” or “losing” or what?

Clifton Leaf is a cancer survivor. He is also the Editor-in-Chief of Fortune magazine. And he has long argued that we may not be making the most astute decisions about how we are trying to find “the best” and “the rightest” ways to diagnose, treat, and manage cancer. … READ MORE …

Preliminary data from the TRITON 2 trial of rucaparib in mCRPC

A poster presented at the ESMO meeting in Munich has just reported data from an unplanned, preliminary analysis of data from the first 85 patients (out of a scheduled total of 150 patients) enrolled in the TRITON 2 trial of the PARP inhibitor rucaparib (Rubraca) … READ MORE …

New data shows that local prostate radiotherapy improves OS in some men with newly diagnosed, metastatic prostate cancer

New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …

Using low-dose abiraterone acetate with food (or a standard dose with no food)

We have known for some time that abiraterone acetate 250 mg, when given with food, appears to have activity that may — in at least some patients — be comparable to the activity of abiraterone acetate 1,000 mg given without food. … READ MORE …

Is anyone with intermediate-risk prostate cancer a “good” candidate for AS?

There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …

Gallium-68 PSMA PET scanning “is a game changer” in prostate cancer

The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …

Examining “value” in the management of prostate cancer

Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …